XFOR - X4 Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
14.04
+0.33 (+2.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.71
Open13.80
Bid0.00 x 800
Ask0.00 x 1100
Day's Range13.45 - 14.50
52 Week Range6.90 - 29.46
Volume112,811
Avg. Volume29,014
Market Cap173.701M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.72
Earnings DateNov 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
Trade prices are not sourced from all markets
  • Business Wire

    X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Renato Skerlj, Ph.D., as Senior Vice President, Research and Development. Dr. Skerlj has twenty-five years of experience leading the discovery and development of small molecule drugs to treat rare diseases, cancer, infection and neurodegenerative diseases. In addition, he was one of the original founders of X4 Pharmaceuticals.

  • Business Wire

    X4 Pharmaceuticals to Attend Two Upcoming Investor Conferences

    X4 Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team is scheduled to conduct one-on-one meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies, and to present and conduct one-on-one meetings at the 2019 Cantor Global Healthcare ...

  • Business Wire

    X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society for Medical Oncology (ESMO) 2019 Congress

    X4 Pharmaceuticals, Inc. (XFOR), a clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of rare diseases, today announced it will present clinical data on its lead product candidate, mavorixafor (X4P-001), in combination with Inlyta® (axitinib) at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress, taking place September 27 – October 1 in Barcelona, Spain. The presentation will detail final safety and efficacy results from the Company’s Phase 2a portion of an open-label Phase 1/2 clinical trial of mavorixafor in combination with axitinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

  • Business Wire

    X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that, on August 28, 2019, the Compensation Committee of X4’s Board of Directors issued inducement awards to two new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 14,250 shares of its common stock and were granted as an inducement material to the new employee entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire

    X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of 4WHIM, a pivotal Phase 3 global clinical trial of mavorixafor (X4P-001) for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease. “Despite the severity of the disease and its significant burden on patients’ long-term health and daily quality of life, WHIM is often overlooked and misdiagnosed.

  • X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
    Business Wire

    X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Invitae Corporation (NVTA), a leader in medical genetics, today announced a partnership to provide genetic testing at no cost to patients through its collaborative PATH4WARD program. This initiative provides greater access to faster and earlier diagnosis for individuals who may carry a genetic mutation known to be associated with WHIM syndrome and Severe Congenital Neutropenia (SCN) – a group of rare inherited primary immunodeficiencies (PIs).

  • Business Wire

    X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and The Leukemia & Lymphoma Society (LLS) today announced a collaboration to accelerate the development of X4’s lead product candidate, mavorixafor (X4P-001) for the treatment of Waldenström’s macroglobulinemia (WM), a rare form of non-Hodgkin lymphoma.

  • Business Wire

    X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of E. Lynne Kelley, M.D., FACS, as the company’s Chief Medical Officer (CMO). Dr. Kelley brings more than a decade of experience driving clinical development and global expansion of novel pharmaceutical products at both emerging and established life sciences companies.

  • Business Wire

    X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 2,130,000 shares of common stock, and accompanying Class A warrants to purchase 3,900,000 shares of its common stock at a price to the public of $11.00 per share and accompanying Class A warrant (or $10.999 per pre-funded warrant and accompanying Class A warrant). X4’s gross proceeds from this offering are expected to be approximately $85.8 million, before deducting underwriting discounts and estimated offering expenses.

  • Business Wire

    X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Class A warrants to purchase its common stock. All of the securities in the offering will be sold by X4.

  • Business Wire

    X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Murray Stewart, M.D., as an independent member of the X4 Board of Directors. “We’re very pleased to welcome Dr. Stewart to the X4 Board,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.

  • Business Wire

    X4 Pharmaceuticals Provides Business and Clinical Development Update

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today provided a business and clinical development update. “This has been a transformative period for X4 with our listing on Nasdaq, finalization of our Phase 3 clinical protocol in WHIM syndrome and the recent approval from the WHO for the use of mavorixafor as our lead candidate name for X4P-001,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.